---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045324"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:36:08.419301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's

## Summary
- Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.
- Cash and equivalents $16.4M plus $47M in NIH grants; runway into Q4 2025.
- Requested End-of-Phase 2 meeting with FDA to discuss Alzheimer's SHINE study and registrational trial.
- Phase 2 SHIMMER study in dementia with Lewy bodies accepted for oral presentation at AAIC July 2025.
- Presenting two posters at ARVO on zervimesine's role in regulating lipid metabolism and retinal cell protection.

## SEC filing metadata
- accession: 0001104659-25-045324
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/0001104659-25-045324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/tm2514197d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045324
- JSON: https://secwatch.observer/filing/0001104659-25-045324.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.